J Clin Neurol.  2016 Jul;12(3):345-350. 10.3988/jcn.2016.12.3.345.

Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension

• Dagan A
• Gringouz I
• Kliers I
• Segal G

• KMID: 2354123
• DOI: http://doi.org/10.3988/jcn.2016.12.3.345

Abstract

BACKGROUND AND PURPOSE
We assessed the prevalence and potential association of hypertension with multiple sclerosis (MS)-related disability progression.
METHODS
This was a retrospective study of 2,813 patients who were followed for 20 years. We modeled the associations of several risk factors with the pattern of disability progression. The primary end point was the rate of disability progression.
RESULTS
In total, 2,396 patients were available for analysis, of which 1,074 (44.8%) scored 4 (EDSS4) on the Expanded Disability Status Scale (EDSS), 717 (29.9%) scored 6 (EDSS6), and 261 (10.9%) scored 8 (EDSS8). The mean times to reach scores of 4, 6, and 8 were 123.5, 163.1, and 218.9 months, respectively. Hypertension was present in 207 (8.6%) patients during follow-up. Hypertension was associated with a higher probability of reaching each EDSS score compared to non-hypertensive patients: 62% vs. 43% for EDSS4 (p<0.01), 51% vs. 28% for EDSS6 (p<0.01), and 17% vs. 10% for EDSS8 (p<0.01). Nevertheless, hypertensive MS patients experienced longer intervals to reach each EDSS score: longer by 51.6, 38.9, and 62.7 months to EDSS4, EDSS6, and EDSS8, respectively (p<0.01) when compared to non-hypertensive MS patients reaching the same EDSS scores.
CONCLUSIONS
Disability progression is more prevalent amongst hypertensive MS patients. However, they experience longer time intervals between the stages of disability progression.

Keyword

multiple sclerosis; hypertension; risk factor; epidemiology; disability; atherosclerosis

MeSH Terms

Atherosclerosis
Epidemiology
Follow-Up Studies
Humans
Hypertension*
Multiple Sclerosis*
Prevalence
Retrospective Studies
Risk Factors

Figure

• 

  Fig. 1 Regression analysis of disease progression to EDSS4 (A), EDSS6 (B), and EDSS8 (C) according to age at disease onset. EDSS: Expanded Disability Status Scale.

Reference

1. Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014; 122:343–369.

2. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122:231–266.

3. Koch M, Uyttenboogaart M, van Harten A, De Keyser J. Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler. 2008; 14:799–803.

4. Newbould RD, Nicholas R, Thomas CL, Quest R, Lee JS, Honeyfield L, et al. Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. Neuroimage Clin. 2014; 4:641–648.

5. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010; 74:2004–2015.

6. Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. PLoS One. 2014; 9:e92761.

7. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014; 13:981–1000.

8. Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B. New York State Multiple Sclerosis Consortium. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler. 2015; 21:858–865.

9. Wesnes K, Riise T, Casetta I, Drulovic J, Granieri E, Holmøy T, et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. Mult Scler. 2015; 21:388–395.

10. O'Gorman C, Broadley SA. Smoking and multiple sclerosis: evidence for latitudinal and temporal variation. J Neurol. 2014; 261:1677–1683.

11. Jawahar R, Oh U, Eaton C, Wright N, Tindle H, Lapane KL. Association between smoking and health outcomes in postmenopausal women living with multiple sclerosis. Mult Scler Int. 2014; 2014:686045.

12. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015; 14:263–273.

13. Gustavsen MW, Page CM, Moen SM, Bjølgerud A, Berg-Hansen P, Nygaard GO, et al. Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. BMC Neurol. 2014; 14:196.

14. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010; 74:1041–1047.

15. Tettey P, Simpson S Jr, Taylor BV, van der Mei IA. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci. 2014; 347:23–33.

16. Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler. 2012; 18:1310–1319.

17. Simpson RJ, McLean G, Guthrie B, Mair F, Mercer SW. Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis. BMC Neurol. 2014; 14:128.

18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33:1444–1452.

19. Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008; 31:1–9.

20. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994; 36:Suppl. S73–S79.

21. Pankuweit S, Wädlich A, Meyer E, Portig I, Hufnagel G, Maisch B. Cytokine activation in pericardial fluids in different forms of pericarditis. Herz. 2000; 25:748–754.

22. Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol. 2008; 255:697–702.

23. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013; 3:e003423.

24. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015; 14:263–273.

25. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler. 2015; 21:318–331.

26. Wens I, Dalgas U, Stenager E, Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Mult Scler. 2013; 19:1556–1564.